CARDIAC STRUCTURE AND FUNCTION IN PATIENTS TREATED WITH PROTEASOME INHIBITORS FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
| Autor: | Daniel J. Lenihan, Bonnie Ky, Ravinder Mallugari, Deepak Gupta, Robert F. Cornell, Cherie N. Dahm |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Bortezomib business.industry Refractory Multiple Myeloma Carfilzomib chemistry.chemical_compound Proteasome chemistry immune system diseases hemic and lymphatic diseases Internal medicine medicine Pi Cardiac structure Cardiology and Cardiovascular Medicine Adverse effect business Function (biology) medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 75:1085 |
| ISSN: | 0735-1097 |
| Popis: | Proteosome inhibitors (PI) are standard therapies for relapsed and/or refractory multiple myeloma (RRMM). Carfilzomib (CAR), an irreversible PI, is associated with greater risk of cardiovascular adverse events (CVAE) compared to bortezomib (BOR), a reversible PI. Whether PIs induce changes in |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|